{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:22:01Z","timestamp":1793784121409,"version":"4.6.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Movement fluctuations are the main complication of Parkinson's disease (PD) patients receiving long-term levodopa (L-dopa) treatment. We compared and ranked the efficacy and safety of dopamine agonists (DAs) with regard to motor fluctuations by using a Bayesian network meta-analysis (NMA) to quantify information from randomized controlled trials (RCTs).<\/jats:p><jats:p><jats:bold>Methods and Findings:<\/jats:bold> We carried out a systematic review and meta-analysis, and only RCTs comparing DAs for advanced PD were included. Electronic databases (PubMed, Embase, and Cochrane Library) were systematically searched for relevant studies published until January 2021. Two reviewers independently extracted individual study data and evaluated studies for risk of bias using the Cochrane Risk of Bias tool. Network meta-analyses using a Bayesian framework were used to calculate the related parameters. The pre-specified primary and secondary outcomes were efficacy (\u201cON\u201d time without troublesome dyskinesia, \u201cOFF\u201d time, \u201cON\u201d time, \u201cUPDRS-III,\u201d and \u201cUPDRS-II\u201d) and safety [treatment-emergent adverse events (TEAE) and other adverse events] of DAs. The results are presented as the surface under the cumulative ranking (SUCRA) curve. A total of 20 RCTs assessing 6,560 patients were included. The general DA effects were ranked from high to low with respect to the amount of \u201cON\u201d time without troublesome dyskinesia as follows: apomorphine (SUCRA = 97.08%), pramipexole_IR (probability = 79.00%), and ropinirole_PR (SUCRA = 63.92%). The general safety of DAs was ranked from high to low with respect to TEAE as follows: placebo (SUCRA = 74.49%), pramipexole_ER (SUCRA = 63.6%), sumanirole (SUCRA = 54.07%), and rotigotine (SUCRA = 53.84%).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This network meta-analysis shows that apomorphine increased \u201cON\u201d time without troublesome dyskinesia and decreased \u201cOF\u201d time for advanced PD patients. The addition of pramipexole, ropinirole, or rotigotine to levodopa treatment in advanced PD patients with motor fluctuations increased \u201cON\u201d time without troublesome dyskinesia, improved the UPDRS III scores, and ultimately ameliorated the UPDRS II scores, thereby maximizing its benefit. This NMA of pramipexole, ropinirole, and rotigotine represents an effective treatment option and has an acceptable safety profile in patients with advanced PD.<\/jats:p>","DOI":"10.3389\/fnins.2021.728083","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T07:15:01Z","timestamp":1635491701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta-Analysis of Double-Blind Randomized Controlled Trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Xinglin","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","article-title":"Medical and surgical management of advanced Parkinson's disease","volume":"33","author":"Antonini","year":"2018","journal-title":"Mov. Disord"},{"key":"B2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov. Disord"},{"key":"B3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"f3675","DOI":"10.1136\/bmj.f3675","article-title":"Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review","volume":"347","author":"Bafeta","year":"2013","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mds.21191","article-title":"Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease","volume":"22","author":"Barone","year":"2007","journal-title":"Mov. Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions","volume":"64","author":"Brozek","year":"2009","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1136\/archdischild-2018-315224","article-title":"Network meta-analysis explained","volume":"104","author":"Dias","year":"2019","journal-title":"Arch. Dis. Child Fetal Neonatal Ed"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181504","article-title":"Canadian guideline for Parkinson disease","volume":"191","author":"Grimes","year":"2019","journal-title":"CMAJ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/bmj.b5614","article-title":"Diagnosis and pharmacological management of Parkinson's disease: summary of SIGN guidelines","author":"Grosset","year":"2010","journal-title":"BMJ"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","article-title":"Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International pramipexole-bromocriptine study group","volume":"49","author":"Guttman","year":"1997","journal-title":"Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hauser","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.23040","article-title":"Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations","volume":"25","author":"Hersh","year":"2010","journal-title":"Mov. Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet. Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000486252","article-title":"Comparison of the efficacy of different drugs on non-motor symptoms of Parkinson's disease: a network meta-analysis","volume":"45","author":"Li","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323656","article-title":"Comparison of efficacy of deep brain stimulation and focused ultrasound in parkinsonian tremor: a systematic review and network meta-analysis","author":"Lin","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/clpt.2008.143","article-title":"Thorough QT\/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine","volume":"84","author":"Malik","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/gps.4834","article-title":"Efficacy and tolerability of antidepressants in Parkinson's disease: a systematic review and network meta-analysis","volume":"33","author":"Mills","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/mds.21313","article-title":"Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study","volume":"22","author":"Mizuno","year":"2007","journal-title":"Mov. Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.parkreldis.2014.10.005","article-title":"Rotigotine vs. ropinirole in advanced stage Parkinson's disease: a double-blind study","volume":"20","author":"Mizuno","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/WNF.0b013e31825f77b9","article-title":"Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial","volume":"35","author":"Mizuno","year":"2012","journal-title":"Clin. Neuropharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/mds.10508","article-title":"Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease","volume":"18","author":"Mizuno","year":"2003","journal-title":"Mov. Disord"},{"key":"B28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov. Disord"},{"key":"B29","volume-title":"National Institute for Health and Care Excellence: Clinical Guidelines, Parkinson's disease in adults: diagnosis and management","year":"2017"},{"key":"B30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JPD-130320","article-title":"A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease","volume":"4","author":"Nicholas","year":"2014","journal-title":"J. Parkinson's Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00415-014-7427-3","article-title":"Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial","volume":"261","author":"Nomoto","year":"2014","journal-title":"J. Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(13)62418-6","article-title":"The expanding universe of disorders of the basal ganglia","volume":"384","author":"Obeso","year":"2014","journal-title":"Lancet (London, England)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"171519","DOI":"10.1098\/rsos.171519","article-title":"Bayesian model evidence as a practical alternative to deviance information criterion","volume":"5","author":"Pooley","year":"2018","journal-title":"R. Soc. Open Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/mds.26362","article-title":"New treatments for levodopa-induced motor complications","volume":"30","author":"Rascol","year":"2015","journal-title":"Mov. Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"A390","DOI":"10.1016\/j.jval.2014.08.856","article-title":"A systematic review and network meta-analysis of pharmacological therapies used for patients with advanced Parkinson's disease","volume":"17","author":"Ren","year":"2014","journal-title":"Value Health"},{"key":"B38","doi-asserted-by":"publisher","first-page":"j1951","DOI":"10.1136\/bmj.j1951","article-title":"Parkinson's disease: summary of updated NICE guidance","volume":"358","author":"Rogers","year":"2017","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","article-title":"Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial","volume":"77","author":"Schapira","year":"2011","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","article-title":"PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease","volume":"26","author":"Stocchi","year":"2011","journal-title":"Mov. Disord"},{"key":"B41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.23517","article-title":"Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease","volume":"26","author":"Stowe","year":"2011","journal-title":"Mov. Disord."},{"key":"B42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11910-002-0006-5","article-title":"Parkinson's disease: medical treatment of moderate to advanced disease","volume":"2","author":"Suchowersky","year":"2002","journal-title":"Curr. Neurol. Neurosci. Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/096228020101000404","article-title":"Bayesian methods in meta-analysis and evidence synthesis","volume":"10","author":"Sutton","year":"2001","journal-title":"Stat. Methods Med. Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2147\/ndt.S60061","article-title":"Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis","volume":"10","author":"Thorlund","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2047-9158-3-11","article-title":"The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study","volume":"3","author":"Wang","year":"2014","journal-title":"Transl. Neurodegener"},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0022-510X(03)00217-X","article-title":"Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease","volume":"216","author":"Wong","year":"2003","journal-title":"J. Neurol. Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/nmt-2016-0038","article-title":"A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease","volume":"7","author":"Zesiewicz","year":"2017","journal-title":"Neurodegen. Dis. Manag"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.parkreldis.2013.07.009","article-title":"The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study","volume":"19","author":"Zhang","year":"2013","journal-title":"Parkinsonism Relat. Disord"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.parkreldis.2017.08.015","article-title":"Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: a randomized, double-blind, placebo-controlled pivotal study","volume":"44","author":"Zhang","year":"2017","journal-title":"Parkinsonism Relat. Disord"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s12325-019-00938-1","article-title":"Indirect comparison of ropinirole and pramipexole as levodopa adjunctive therapy in advanced Parkinson's disease: a systematic review and network meta-analysis","volume":"36","author":"Zhao","year":"2019","journal-title":"Adv. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"45865","DOI":"10.1038\/srep45865","article-title":"Comparison for efficacy and tolerability among ten drugs for treatment of Parkinson's disease: a network meta-analysis","volume":"8","author":"Zhuo","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.728083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T07:15:04Z","timestamp":1635491704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2021.728083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":51,"alternative-id":["10.3389\/fnins.2021.728083"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2021.728083","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"article-number":"728083"}}